GeriLABS, the acronym for our study titled “Longitudinal
Biomarkers for characterisation of early
Sarcopenia and predicting frailty and functional decline in community-dwelling Asian older adults”, aims to develop a clinical/biomarker phenotype for the prediction of frailty and functional decline in community-dwelling older adults.
Started since 2013, we recruited older participants from the community to undergo a series of clinical and physical assessments, imaging scans and blood tests over a span of 5 years.
With the successful conclusion of our first phase in 2018, the team organised appreciation forums for our participants and community partners to share about the study findings alongside strategies for the prevention of sarcopenia and sarcopenic obesity.
A firm believer of giving back to the community, these get-togethers allowed our deepest gratitude to the participants, for their trust and time journeying with us. We also lauded their spirit of giving back to the society for medical advancements, including three nonagenarian participants aged 92-98 years old.
Following the success of GeriLABS, we embarked on our second wave (GeriLABS 2) in December 2017, studying the interplay of bones, muscles and fats.
Our GeriLABS 1 and 2 studies have created a strong foothold in raising awareness of sarcopenia and frailty, and more recently, osteosarcopenic obesity. Following through our Asian cohorts of community-dwelling older adults, we are excited to push the frontiers of knowledge and contribute to future developments in this emerging field.
Find out more about our study team and accolades below: